{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:31:52Z","timestamp":1790875912406,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00277-024-06063-6","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T01:02:12Z","timestamp":1729818132000},"page":"5527-5537","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of tucidinostat with CHOP-like versus CHOP-like in first-line treatment of peripheral T-cell lymphoma: a single-center real-world study"],"prefix":"10.1007","volume":"103","author":[{"given":"Xiaolian","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinchuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei\u2019e","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"6063_CR1","doi-asserted-by":"crossref","unstructured":"The Non-Hodgkin\u2019s Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. Blood 89(11):3909\u20133918","DOI":"10.1182\/blood.V89.11.3909"},{"key":"6063_CR2","unstructured":"Rangoonwala HI, Cascella M Peripheral T-Cell lymphoma. [Updated 2022 Aug 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2023 Jan 2023 June 8]; https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK562301\/"},{"key":"6063_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/978-3-319-99716-2_4","volume-title":"T-Cell and NK-Cell Lymphomas: from Biology to Novel therapies","author":"A Oluwasanjo","year":"2019","unstructured":"Oluwasanjo A et al (2019) Peripheral T-Cell lymphoma, not otherwise specified (PTCL-NOS). In:Querfeld C, Zain J, Rosen ST (eds). T-Cell and NK-Cell Lymphomas: from Biology to Novel therapies.. Springer, Cham, pp.83\u201398."},{"issue":"7","key":"6063_CR4","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/ajh.24791","volume":"92","author":"JO Armitage","year":"2017","unstructured":"Armitage JO (2017) The aggressive peripheral T-cell lymphomas: 2017. Am J Hematol 92(7):706\u2013715","journal-title":"Am J Hematol"},{"issue":"9","key":"6063_CR5","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.3390\/cancers14092332","volume":"14","author":"D Sibon","year":"2022","unstructured":"Sibon D (2022) Peripheral T-Cell lymphomas: therapeutic approaches. Cancers 14(9):2332","journal-title":"Cancers"},{"issue":"7","key":"6063_CR6","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/cncr.30416","volume":"123","author":"KR Carson","year":"2017","unstructured":"Carson KR et al (2017) A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer 123(7):1174\u20131183","journal-title":"Cancer"},{"issue":"11","key":"6063_CR7","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.clml.2022.06.012","volume":"22","author":"LAdPC Lage","year":"2022","unstructured":"Lage LAdPC et al (2022) Up-front therapy with CHOP plus etoposide in Brazilian nodal ptcl patients: increased toxicity and no survival benefit compared to CHOP regimen\u2013results of a real-life study from a middle-income country. Clin Lymphoma Myeloma Leuk 22(11):812\u2013824","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"6063_CR8","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1182\/blood.2021015114","volume":"140","author":"M Brink","year":"2022","unstructured":"Brink M et al (2022) Impact of etoposide and ASCT on survival among patients aged & lt;65 years with stage II to IV PTCL: a population-based cohort study. Blood 140(9):1009\u20131019","journal-title":"Blood"},{"key":"6063_CR9","first-page":"623924","volume":"2011","author":"AN Abouyabis","year":"2011","unstructured":"Abouyabis AN et al (2011) A systematic review and Meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-Cell lymphoma. ISRN Hematol 2011:623924","journal-title":"ISRN Hematol"},{"issue":"1","key":"6063_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13148-020-00962-x","volume":"12","author":"P Zhang","year":"2020","unstructured":"Zhang P, Zhang M (2020) Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma. Clin Epigenetics 12(1):169","journal-title":"Clin Epigenetics"},{"issue":"4","key":"6063_CR11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11912-017-0582-9","volume":"19","author":"RF Sandell","year":"2017","unstructured":"Sandell RF, Boddicker RL, Feldman AL (2017) Genetic Landscape and classification of Peripheral T Cell Lymphomas. Curr Oncol Rep 19(4):28","journal-title":"Curr Oncol Rep"},{"key":"6063_CR12","doi-asserted-by":"crossref","unstructured":"Sun Y et al (2022) Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment. Front Pharmacol 13:932914","DOI":"10.3389\/fphar.2022.932914"},{"issue":"3","key":"6063_CR13","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3324\/haematol.2022.280996","volume":"108","author":"S Rai","year":"2023","unstructured":"Rai S et al (2023) Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results. Haematologica 108(3):811\u2013821","journal-title":"Haematologica"},{"issue":"3","key":"6063_CR14","doi-asserted-by":"publisher","first-page":"841","DOI":"10.20892\/j.issn.2095-3941.2020.0413","volume":"18","author":"W Zhang","year":"2021","unstructured":"Zhang W et al (2021) The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b\/2 study. Cancer Biol Med 18(3):841\u2013848","journal-title":"Cancer Biol Med"},{"issue":"5","key":"6063_CR15","doi-asserted-by":"publisher","first-page":"616","DOI":"10.21147\/j.issn.1000-9604.2021.05.08","volume":"33","author":"L Gui","year":"2021","unstructured":"Gui L et al (2021) Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma. Chin J Cancer Res 33(5):616\u2013626","journal-title":"Chin J Cancer Res"},{"key":"6063_CR16","doi-asserted-by":"crossref","unstructured":"Wang J et al (2022) Comparison of Chemotherapy Combined with Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma. Front Immunol 13:835103","DOI":"10.3389\/fimmu.2022.835103"},{"issue":"5","key":"6063_CR17","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114(5):937\u2013951","journal-title":"Blood"},{"issue":"4","key":"6063_CR18","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s11899-010-0062-x","volume":"5","author":"PP Piccaluga","year":"2010","unstructured":"Piccaluga PP et al (2010) Prognostic markers in peripheral T-Cell lymphoma. Curr Hematol Malig Rep 5(4):222\u2013228","journal-title":"Curr Hematol Malig Rep"},{"issue":"21","key":"6063_CR19","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD et al (2016) Refinement of the Lugano Classification Lymphoma response criteria in the era of immunomodulatory therapy. Blood 128(21):2489\u20132496","journal-title":"Blood"},{"key":"6063_CR20","unstructured":"Protocol Development. Common terminology criteria for adverse events. (CTCAE) [updated 2021 April 19] (2023) June 8]; https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm"},{"issue":"5","key":"6063_CR21","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1093\/annonc\/mdn022","volume":"19","author":"S Mercadal","year":"2008","unstructured":"Mercadal S et al (2008) Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 19(5):958\u2013963","journal-title":"Ann Oncol"},{"issue":"1","key":"6063_CR22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","volume":"27","author":"P Reimer","year":"2009","unstructured":"Reimer P et al (2009) Autologous stem-cell transplantation as first-line therapy in peripheral T-Cell lymphomas: results of a prospective multicenter study. J Clin Oncol 27(1):106\u2013113","journal-title":"J Clin Oncol"},{"issue":"25","key":"6063_CR23","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F d\u2019Amore","year":"2012","unstructured":"d\u2019Amore F et al (2012) Up-front autologous stem-cell transplantation in peripheral T-Cell lymphoma: NLG-T-01. J Clin Oncol 30(25):3093\u20133099","journal-title":"J Clin Oncol"},{"issue":"3","key":"6063_CR24","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/annonc\/mdx787","volume":"29","author":"G Fossard","year":"2018","unstructured":"Fossard G et al (2018) Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol 29(3):715\u2013723","journal-title":"Ann Oncol"},{"issue":"3","key":"6063_CR25","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.21.01815","volume":"40","author":"E Bachy","year":"2022","unstructured":"Bachy E et al (2022) Romidepsin plus CHOP Versus CHOP in patients with previously untreated peripheral T-Cell lymphoma: results of the Ro-CHOP Phase III study (conducted by LYSA). J Clin Oncol 40(3):242\u2013251","journal-title":"J Clin Oncol"},{"issue":"4","key":"6063_CR26","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.biopha.2014.03.011","volume":"68","author":"Y Zhou","year":"2014","unstructured":"Zhou Y et al (2014) Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in non-small-cell lung cancer cells. Biomed Pharmacother 68(4):483\u2013491","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"6063_CR27","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1039\/C4MD00350K","volume":"5","author":"D-S Pan","year":"2014","unstructured":"Pan D-S et al (2014) Discovery of an orally active subtype-selective HDAC inhibitor, chidamide, as an epigenetic modulator for cancer treatment. MedChemComm 5(12):1789\u20131796","journal-title":"MedChemComm"},{"key":"6063_CR28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-016-0243-8","volume":"9","author":"F Foss","year":"2016","unstructured":"Foss F et al (2016) Romidepsin for the treatment of relapsed\/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol 9:22","journal-title":"J Hematol Oncol"},{"key":"6063_CR29","doi-asserted-by":"publisher","first-page":"875469","DOI":"10.3389\/fonc.2022.875469","volume":"12","author":"W Guo","year":"2022","unstructured":"Guo W et al (2022) Chidamide Maintenance Therapy Following Induction Therapy in patients with peripheral T-Cell Lymphoma who are Ineligible for autologous stem cell transplantation: Case Series from China. Front Oncol 12:875469","journal-title":"Front Oncol"},{"issue":"12","key":"6063_CR30","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","volume":"111","author":"KJ Savage","year":"2008","unstructured":"Savage KJ et al (2008) ALK\u2009\u2013\u2009anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK\u2009+\u2009ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 111(12):5496\u20135504","journal-title":"Blood"},{"issue":"5","key":"6063_CR31","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/ajh.26499","volume":"97","author":"Y Wang","year":"2022","unstructured":"Wang Y et al (2022) Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: a multicenter phase II trial. Am J Hematol 97(5):623\u2013629","journal-title":"Am J Hematol"},{"issue":"15","key":"6063_CR32","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1182\/blood-2015-05-644591","volume":"126","author":"C Wang","year":"2015","unstructured":"Wang C et al (2015) IDH2 R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood 126(15):1741\u20131752","journal-title":"Blood"},{"issue":"4","key":"6063_CR33","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/hon.2320","volume":"35","author":"B Pro","year":"2017","unstructured":"Pro B et al (2017) Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma. Hematol Oncol 35(4):914\u2013917","journal-title":"Hematol Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06063-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06063-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06063-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:11:50Z","timestamp":1735866710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06063-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6063"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06063-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]},"assertion":[{"value":"24 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Studies involving human participants were reviewed and approved by the review board of Shanxi Cancer Hospital(KY2023069).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients included in the study provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}